Cargando…
Prognostic utility of human complement factor H related protein test (the BTA stat® Test)
The purpose of the study was to determine, in addition to well-known prognostic factors, histological grade, stage, tumour size and multiplicity, the correlation of BTA stat Test on disease free interval (DFI) on primary superficial bladder cancer. A total of 116 patients with newly diagnosed bladde...
Autores principales: | , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2001
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2364089/ https://www.ncbi.nlm.nih.gov/pubmed/11506495 http://dx.doi.org/10.1054/bjoc.2001.1938 |
_version_ | 1782153866966466560 |
---|---|
author | Raitanen, M-P Kaasinen, E Rintala, E Hansson, E Nieminen, P Aine, R Tammela, T L J |
author_facet | Raitanen, M-P Kaasinen, E Rintala, E Hansson, E Nieminen, P Aine, R Tammela, T L J |
author_sort | Raitanen, M-P |
collection | PubMed |
description | The purpose of the study was to determine, in addition to well-known prognostic factors, histological grade, stage, tumour size and multiplicity, the correlation of BTA stat Test on disease free interval (DFI) on primary superficial bladder cancer. A total of 116 patients with newly diagnosed bladder cancer were evaluated in a prospective multicentre study. A voided urine sample was obtained prior to TURB and split for culture, cytology and BTA stat testing. Follow-up data for the patients were collected until the first recurrence or the last visit and the DFI was analysed by Kaplan–Meier method and Cox analysis. Ninety-seven of the 116 (83.6%) patients were eligible for analysis. The BTA stat Test was positive in 73 (75.3%) patients, whereas cytology detected 20 (20.6%) cases. The DFI was found to be shorter among patients with a positive BTA stat Test, and also among those with intermediate or high-grade tumours. The BTA stat Test result divided patients with grade 2 tumours into two prognostic groups, in that those testing positive had 68.6% risk of recurrence during the first year compared to 42.9% risk of those with a negative test result (P = 0.041). Although the effect of tumour size on DFI was notable, the difference did not reach statistical significance (P = 0.064). Number of tumours was not related to DFI, nor was the difference between different stage of tumour of significance. BTA stat Test is not only sensitive in detection of primary bladder cancer, but also might have some independent prognostic significance. © 2001 Cancer Research Campaign http://www.bjcancer.com |
format | Text |
id | pubmed-2364089 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2001 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-23640892009-09-10 Prognostic utility of human complement factor H related protein test (the BTA stat® Test) Raitanen, M-P Kaasinen, E Rintala, E Hansson, E Nieminen, P Aine, R Tammela, T L J Br J Cancer Regular Article The purpose of the study was to determine, in addition to well-known prognostic factors, histological grade, stage, tumour size and multiplicity, the correlation of BTA stat Test on disease free interval (DFI) on primary superficial bladder cancer. A total of 116 patients with newly diagnosed bladder cancer were evaluated in a prospective multicentre study. A voided urine sample was obtained prior to TURB and split for culture, cytology and BTA stat testing. Follow-up data for the patients were collected until the first recurrence or the last visit and the DFI was analysed by Kaplan–Meier method and Cox analysis. Ninety-seven of the 116 (83.6%) patients were eligible for analysis. The BTA stat Test was positive in 73 (75.3%) patients, whereas cytology detected 20 (20.6%) cases. The DFI was found to be shorter among patients with a positive BTA stat Test, and also among those with intermediate or high-grade tumours. The BTA stat Test result divided patients with grade 2 tumours into two prognostic groups, in that those testing positive had 68.6% risk of recurrence during the first year compared to 42.9% risk of those with a negative test result (P = 0.041). Although the effect of tumour size on DFI was notable, the difference did not reach statistical significance (P = 0.064). Number of tumours was not related to DFI, nor was the difference between different stage of tumour of significance. BTA stat Test is not only sensitive in detection of primary bladder cancer, but also might have some independent prognostic significance. © 2001 Cancer Research Campaign http://www.bjcancer.com Nature Publishing Group 2001-08 /pmc/articles/PMC2364089/ /pubmed/11506495 http://dx.doi.org/10.1054/bjoc.2001.1938 Text en Copyright © 2001 Cancer Research Campaign https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Regular Article Raitanen, M-P Kaasinen, E Rintala, E Hansson, E Nieminen, P Aine, R Tammela, T L J Prognostic utility of human complement factor H related protein test (the BTA stat® Test) |
title | Prognostic utility of human complement factor H related protein test (the BTA stat® Test) |
title_full | Prognostic utility of human complement factor H related protein test (the BTA stat® Test) |
title_fullStr | Prognostic utility of human complement factor H related protein test (the BTA stat® Test) |
title_full_unstemmed | Prognostic utility of human complement factor H related protein test (the BTA stat® Test) |
title_short | Prognostic utility of human complement factor H related protein test (the BTA stat® Test) |
title_sort | prognostic utility of human complement factor h related protein test (the bta stat® test) |
topic | Regular Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2364089/ https://www.ncbi.nlm.nih.gov/pubmed/11506495 http://dx.doi.org/10.1054/bjoc.2001.1938 |
work_keys_str_mv | AT raitanenmp prognosticutilityofhumancomplementfactorhrelatedproteintestthebtastattest AT kaasinene prognosticutilityofhumancomplementfactorhrelatedproteintestthebtastattest AT rintalae prognosticutilityofhumancomplementfactorhrelatedproteintestthebtastattest AT hanssone prognosticutilityofhumancomplementfactorhrelatedproteintestthebtastattest AT nieminenp prognosticutilityofhumancomplementfactorhrelatedproteintestthebtastattest AT ainer prognosticutilityofhumancomplementfactorhrelatedproteintestthebtastattest AT tammelatlj prognosticutilityofhumancomplementfactorhrelatedproteintestthebtastattest AT prognosticutilityofhumancomplementfactorhrelatedproteintestthebtastattest |